Propanc Biopharma, Inc.
For the period ended Jun 30, 2026. Filed Sep 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Sep 25, 2026
PPCB$1.76-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
The following consolidated financial statements of Propanc Biopharma, Inc. are included in this Annual Report on Form 10-K:
PROPANC BIOPHARMA, INC.
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB Firm ID. 106) | F-1 |
|---|---|
| Consolidated Balance Sheets as of June 30, 2026 and 2025 | F-2 |
| Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended June 30, 2026 and 2025 | F-3 |
| Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the years ended June 30, 2026 and 2025 | F-4 |
| Consolidated Statements of Cash Flows for the years ended June 30, 2026 and 2025 | F-5 |
| Notes to Consolidated Financial Statements | F-6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.